OncoTarget
A unique research and production complex organized on the principle of full integration.
The Company has all the competencies required to develop and manufacture original and generic medicines to treat cancer and other high-profile diseases.
Since 2020, the Company has been based at Technopolis Moscow SEZ.
Company values
High level of social responsibility
Innovative technological solutions
Team
professionalism
Adherence to high ethical principles
Manufacturing
and r&d center
Manufacturing
Manufacturing processes use effective, state-of-the-art equipment from leading foreign companies.
To date, 140 units of high-tech machines of world brands have been purchased, which makes it possible
to consolidate efforts in the development, manufacture and quality control of medicines of various
dosage forms.
Manufacturing capacity:
10 million
packs per year of solid dosage forms6 million
packs per year of sterile dosage forms100 kg
per year of small-volume manufacture of apis for own manufacturing needs
r&d center
Own R&D Center develops original, generic and hybrid drugs based on small molecules of chemical
origin.
We have created a state-of-the-art research and manufacturing platform for the development and
manufacture of our own active pharmaceutical ingredients and finished pharmaceutical products based
on them.
Targeted therapy
According to the World Health Organization, cancer is one of the leading causes of morbidity and
mortality worldwide.
Oncological diseases are systemic and affect all human organs and systems in one way or
another.
550,000
new cases of oncological diseases were registered in russia in 2020High mortality rates from cancer can be reduced if the following conditions are met:
EARLY DIAGNOSIS
CORRECT DIAGNOSIS
USE OF EFFECTIVE MEDICINES
Targeted therapy – a type of drug therapy used to treat oncological diseases, has a targeted effect on intracellular mechanisms that affect tumor growth.
Targeted treatment compares favorably with classical chemotherapy in that it "forces" the patient's
own immune system to selectively attack only cancer cells, causing little or no damage to healthy
cells and body tissues.
Development and registration of antitumor drugs is an urgent task both for the healthcare system as
a whole and specifically for the Russian full-cycle pharmaceutical company OncoTarget.
Product portfolio
86% of the product portfolio is included in the list of Vital and Essential Drugs.
Select category
Oncology / Oncohematology
Endocrinology
Gastroenterology
Gynecology
Intensive therapy
Cardiology
Dermatology
HIV and infectious diseases
Company plans:
more than 18
molecules to treat oncological diseases will appear in the company's portfolio
more than 16 million
packs of drugs will be produced
approximately 50
medicinal products are planned for release
Licenses
OncoTarget manufacturing is in full compliance with international pharmacological industry quality standards.
